| Bioactivity | ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers[1]. | ||||||||||||
| Target | IC50: 9 nM (CSF1R/c-Fms) | ||||||||||||
| Invitro | ARRY-382 (1 µM) dramatically decreases the number of nurse-like cells (NLCs) compared to untreated cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> ARRY-382 相关抗体: | ||||||||||||
| CAS | 1313407-95-2 | ||||||||||||
| Formula | C32H36N8O2 | ||||||||||||
| Molar Mass | 564.68 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. David K Edwards V, et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 2018 May 15;9(37):24576-24589. |